Karyopharm Therapeutics Inc (NAS:KPTI)
$ 1.09 0.02 (1.87%) Market Cap: 126.95 Mil Enterprise Value: 112.52 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 76/100

Karyopharm Therapeutics Inc. Phase 3 BOSTON Study Top-line Results Conference Call Transcript

Mar 02, 2020 / 01:30PM GMT
Release Date Price: $27.72 (+69.65%)
Operator

Good morning. My name is Gigi, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Phase III Boston Study Top Line Results Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Mr. Ian Karp, Karyopharm's Vice President, Investor and Public relations.

Ian Karp
Karyopharm Therapeutics Inc. - VP of Investor & Public Relations

Thank you, Gigi, and thank you all for joining us on today's conference call to discuss the positive top line results from the Phase III BOSTON study. This is Ian Karp, and I'm joined today by Dr. Michael Kauffman, Chief Executive Officer; Mr. Chris Primiano, Chief Business Officer and General Counsel, Mr. Mike Mason, Chief Financial Officer; and Mr. Perry Monaco, Senior Vice President of Sales.

On the call today, Dr. Kauffman will provide a brief overview of the current treatment paradigm for patients with multiple myeloma and highlight the rationale

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot